Cargando…

Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients

By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high ren...

Descripción completa

Detalles Bibliográficos
Autores principales: Costea, AC, Costea, DO, David, C, Grasa, CN
Formato: Texto
Lenguaje:English
Publicado: Carol Davila University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019039/
https://www.ncbi.nlm.nih.gov/pubmed/20302199
_version_ 1782196150565076992
author Costea, AC
Costea, DO
David, C
Grasa, CN
author_facet Costea, AC
Costea, DO
David, C
Grasa, CN
author_sort Costea, AC
collection PubMed
description By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high rennin secretion) and the adaptation of the therapeutic approach to every patient. An individualized dialysis prescription is imposed, taking into account the residual renal function and an anti–hypertension treatment, in which the role of the conversion enzyme inhibitors (ACE inhibitor) is intensely debated.
format Text
id pubmed-3019039
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-30190392011-03-03 Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients Costea, AC Costea, DO David, C Grasa, CN J Med Life General Article By establishing the renal suppletion procedure, the patients with chronic renal failure also have an acceleration of arterial hypertension phenomena. The management of this situation calls for the understanding of the ethological mechanisms (hypervolemia by the reduction of Na excretion and high rennin secretion) and the adaptation of the therapeutic approach to every patient. An individualized dialysis prescription is imposed, taking into account the residual renal function and an anti–hypertension treatment, in which the role of the conversion enzyme inhibitors (ACE inhibitor) is intensely debated. Carol Davila University Press 2010-02-15 2010-02-25 /pmc/articles/PMC3019039/ /pubmed/20302199 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle General Article
Costea, AC
Costea, DO
David, C
Grasa, CN
Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title_full Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title_fullStr Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title_full_unstemmed Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title_short Arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
title_sort arterial hypertension management with conversion enzyme inhibitors in hemodialysis patients
topic General Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019039/
https://www.ncbi.nlm.nih.gov/pubmed/20302199
work_keys_str_mv AT costeaac arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients
AT costeado arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients
AT davidc arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients
AT grasacn arterialhypertensionmanagementwithconversionenzymeinhibitorsinhemodialysispatients